On November 9, 157 organizations representing patients, clinicians, community practices, and infusion centers sent a letter to Representatives Gregory Murphy and Adam Gray urging Congress to enact H.R. 4299 before the 119th Congress adjourns.
The bipartisan bill is described as a “technical fix” to how Medicare Part B drugs are paid once negotiated prices take effect in January 2028. Without it, the signers warn, provider reimbursement for those drugs, including the 4.3 percent add-on payment, could drop by roughly 50 percent, while the costs of storing, handling, and administering them stay the same. They cite an Avalere projection of at least $25 billion in losses across the first 10 negotiated Part B drugs.
H.R. 4299 would keep the current ASP-based payment for providers delivering the same drug, to the same patient, in the same setting. Manufacturers would pay CMS a rebate for the difference between ASP and the negotiated price, so government programs still benefit and patients keep the lower cost-sharing.
The signers argue the stakes are highest for independent community practices and the patients who rely on them, especially in rural areas. If practices stop stocking these therapies, patients may have to travel farther to hospital outpatient departments, where the letter says the same care can cost 38 to 60 percent more.
The letter also stresses timing. CMS needs time to build the policy into its 2028 payment rules, and practices are making hiring and contracting decisions now. The signers ask Congress to include H.R. 4299 in any health care legislation passed before the end of this Congress.




